Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results Total net revenue of $15.2 million Adjusted EBITDA1 of$(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over$22 billion United States prescription major depressive disorder ("MDD") market Company to host confer ...